Mereo BioPharma (MREO) Non-Current Assets (2017 - 2026)

Mereo BioPharma (MREO) has reported Non-Current Assets for 10 consecutive years, with $580000.0 the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Assets fell 59.24% year-over-year to $580000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 46.54% YoY) and the FY2025 annual result came in at $897000.0, down 44.87% from the prior year.
• Non-Current Assets retreated to $580000.0 in Q1 2026 per MREO's latest filing, from $897000.0 in the prior quarter.
• Over the last five years, Non-Current Assets for MREO reached as high as $2.7 million in Q4 2023 and fell as low as -$103.0 million in Q2 2022.
• A 5-year average of -$17.5 million and a median of $1.2 million in 2025 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets jumped 103.76% — and 2026, when it plunged 59.24%.
• Year by year, Non-Current Assets stood at -$72.9 million in 2022, then soared by 103.76% to $2.7 million in 2023, then slumped by 40.6% to $1.6 million in 2024, then tumbled by 44.87% to $897000.0 in 2025, then slumped by 35.34% to $580000.0 in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $580000.0, $897000.0, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.